Compare ESP & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESP | JSPR |
|---|---|---|
| Founded | 1928 | 2018 |
| Country | United States | United States |
| Employees | N/A | 22 |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 171.4M | 23.1M |
| IPO Year | 1995 | N/A |
| Metric | ESP | JSPR |
|---|---|---|
| Price | $71.25 | $0.95 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 11 |
| Target Price | ★ $64.00 | $15.50 |
| AVG Volume (30 Days) | 17.0K | ★ 533.6K |
| Earning Date | 05-13-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.50% | N/A |
| EPS Growth | ★ 31.88 | N/A |
| EPS | ★ 1.75 | N/A |
| Revenue | ★ $43,950,872.00 | N/A |
| Revenue This Year | $10.30 | N/A |
| Revenue Next Year | $10.00 | N/A |
| P/E Ratio | $40.13 | ★ N/A |
| Revenue Growth | ★ 13.46 | N/A |
| 52 Week Low | $30.30 | $0.62 |
| 52 Week High | $73.50 | $7.19 |
| Indicator | ESP | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 63.34 | 47.89 |
| Support Level | $42.46 | $0.81 |
| Resistance Level | $73.50 | $1.12 |
| Average True Range (ATR) | 3.21 | 0.10 |
| MACD | 0.08 | 0.01 |
| Stochastic Oscillator | 74.77 | 42.03 |
Espey Manufacturing & Electronics Corp is a power electronics design and OEM manufacturing company delivering products for military and severe environment applications. Its products include power supplies, power converters, filters, power transformers, magnetic components, power distribution equipment, UPS systems, and antennas. The applications of these products include AC and DC locomotives, shipboard power, shipboard radar, airborne power, ground-based radar, and ground mobile power. Espey services include design and development to specification, build to specifications provided by the customer, build to print, design services, design studies, environmental testing services, metal fabrication, painting services, and development of automatic testing equipment.
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.